Antigen 85B of Mycobacterium tuberculosis: From Immunodominant Antigen to Vaccine Candidate
Vivek Chauhan, Gaytri Mahajan, Rakesh Kumar, Shrikanth S. Gadad, Subhash C. Chauhan, Chinnaswamy Jagannath, Subramanian Dhandayuthapani · 2026
Read Antigen 85B of Mycobacterium tuberculosis: From Immunodominant Antigen to Vaccine Candidate by Vivek Chauhan, Gaytri Mahajan, Rakesh Kumar, Shrikanth S. Gadad, Subhash C. Chauhan, Chinnaswamy Jagannath, Subramanian Dhandayuthapani (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13611855.txt.
Description
Vivek Chauhan and co-authors review antigen 85B, a protein of the tuberculosis germ, as a vaccine candidate, in a review paper from 2026. Tuberculosis still burdens world health despite working drugs. The only licensed vaccine, BCG, protects adults unevenly at best.
The protein helps the germ build its cell wall, stick to host cells, and stir immune response. Vaccine makers have placed it in subunit, DNA, mRNA, and live-carrier designs. Trials in animals and humans show strong cell-based immune response and often better protection. The review weighs the protein's biology and trial record, and argues it belongs at the center of next-generation tuberculosis vaccines.
Catalog record
| CREATOR | Vivek Chauhan, Gaytri Mahajan, Rakesh Kumar, Shrikanth S. Gadad, Subhash C. Chauhan, Chinnaswamy Jagannath, Subramanian Dhandayuthapani |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |